Structure Therapeutics (GPCR): oral GLP-1 aleniglipron shows 16.2% weight loss; Phase 3 underway, cash runway strong. Read ...
GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0% ...
SAN FRANCISCO & SHANGHAI--(BUSINESS WIRE)--Structure Therapeutics Inc. (Structure Therapeutics), formerly known as ShouTi Inc., today announced it closed an oversubscribed $33 million financing round, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results